Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Our study aimed to assess the applicability of miR-486 in combination with soluble GP88 protein as a diagnostic and/or predictive biomarker for prostate cancer (PCa) patients. miR-486 and GP88 levels in serum samples from 136 patients undergoing MRI-guided biopsy of the prostate were assessed by qRT...

Full description

Bibliographic Details
Main Authors: Alexander Fichte, Angela Neumann, Katrin Weigelt, Juan Guzman, Thilo Jansen, Julia Keinert, Ginette Serrero, Binbin Yue, Robert Stöhr, Thomas Greither, Arndt Hartmann, Bernd Wullich, Helge Taubert, Sven Wach, Verena Lieb
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Life
Subjects:
progranulin
miRNAs
prostate cancer
serum level
predictive biomarker
age
Online Access:https://www.mdpi.com/2075-1729/12/5/732

Internet

https://www.mdpi.com/2075-1729/12/5/732

Similar Items